Sprint Bioscience AB Company Description

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.

The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer.

It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash.

Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.

Sprint Bioscience AB (publ)

Country	Sweden
Founded	2009
Industry	Biotechnology
Sector	Healthcare
Employees	38
CEO	Johan Emilsson

Contact Details

Address: Novum Huddinge, Stockholm County 141 57 Sweden
Phone	46 84 11 44 55
Website	sprintbioscience.com

Stock Details

Ticker Symbol	SPRINT
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0006343745
SIC Code	2836

Key Executives

Name	Position
Johan Emilsson	Chief Executive Officer
Prof. Pär Nordlund	Founder
Dr. Martin Andersson	Co-Founder and Chief Scientific Officer
Dr. Kenth Hallberg	Founder and Director of Structural Chemistry
Niklas Axelsson	Chief Financial Officer
Anne-Marie Wenthzel	Chief Business Officer